BACKGROUND: Tuberculosis (TB) is a persistent public health issue requiring consistent global effort for its eradication and control. Research on the subject plays a vital role in combatting the disease, giving future directions, and meeting the sustainable development goals (SDGs). This study aimed to evaluate the global TB research trends and performance from 2011 to 2020. MATERIALS AND METHODS: All the data for TB-related research publications from 2011 to 2020 were extracted from the Web of Science database and a comprehensive analysis was performed on the R-bibliometrix package. RESULTS: An increasing number of publications with an annual growth rate of 6.32% and a plateau in production from 2015 to 2018 was observed. Of 145 countries, the United States of America (USA), China, India, the United Kingdom, and South Africa led and made up half of the global contribution. Out of 91,862 authors, Zhang Y was the most productive with 205 articles and Barry CE had the highest H-index of 45. Only seven of the top 20 authors were from high-burden countries. The University of Cape Town was the leading institutional affiliation, followed by Stellenbosch University and the London School of Hygiene and Tropical Medicine. The most frequent international collaboration was between the USA and South Africa, occurring on 1203 instances. Only five of the top 30 high-burden countries were present in the top 30 collaborations. PLOS ONE, disseminating 2271 articles, was the most productive out of 3500 sources. CONCLUSION: The past decade has seen a steady increase in global TB research. Prominent authors, affiliations, and countries showed collaborative trends, but publications were found to be mostly from developed, low-burden countries except China, India, and South Africa. To meet the goals set by the SDGs and the WHO End TB Strategy, high-burden countries need to explore feasible opportunities and global support to enhance their expected TB-related research contributions.

Background: Ischemic heart disease (IHD) remains the leading cause of mortality globally, contributing significantly to rising healthcare costs. This study aims to analyze trends in IHD-related mortality from 1999 to 2020 using data from the Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Methods: Mortality data from 1999 to 2020 were extracted from the CDC WONDER database, with IHD identified as the primary cause of death (International Classification of Diseases, 10th Revision Codes: I20–I25). Age-adjusted mortality rates (AAMRs) were calculated and analyzed. Trends were assessed using Joinpoint Regression Analysis to determine the annual percentage change (APC). Additionally, predictive modeling was performed using an autoregressive integrated moving average model implemented in Python and Generative Pre-trained Transformer 4. Results: The study observed a decline in AAMR over the 22-year period, totaling 9 105 056 deaths. The APC revealed a significant decline in mortality rates until 2011 [APC: −4.99, P < 0.05, 95% confidence interval (CI): −5.3 to −4.7], followed by a slower decline through 2020 (APC: −2.35, P < 0.05, 95% CI: −2.8 to −1.6). Both males (AAMR: 161.4, 95% CI: 161.3–161.6) and females (AAMR: 93.1, 95% CI: 93.0–93.2) experienced a continuous decline in APC until 2018, after which trends began to reverse. African Americans had the highest AAMR (144.1, 95% CI: 143.8–144.3), followed by Whites (125.3, 95% CI: 125.3–125.4), American Indians (106.1, 95% CI: 105.0–107.2), Hispanics (92.9, 95% CI: 92.7–93.2), and Asians (67.1, 95% CI: 66.8–67.4). Geographically, the Mid-Atlantic region exhibited the highest AAMR, followed by the East South-Central region. Among states, Oklahoma had the highest AAMR, followed by New York. Non-metropolitan areas had the highest mortality rates, whereas large-fringe metropolitan areas exhibited the lowest. Predictive analysis suggests a potential plateau or slight increase in mortality rates by 2035 (AAMR: 104.5, 95% CI: 50.05–159.64). Conclusions: The observed slowing in the decline of IHD mortality rates and the potential for future increases underscore the need for sustained public health interventions and vigilant surveillance to mitigate the burden of IHD.

Background: Cardiac arrest remains a significant public health challenge with variable mortality trends across different demographics and regions, affecting healthcare planning and intervention strategies. We conducted this study to analyze cardiac arrest-related mortality trends from 1999 to 2023 and predict future trends up to 2035. Methods: This study analyzed data from 1999 to 2023, focusing on cardiac arrest as the primary cause of death (ICD-10: I46). Age-adjusted mortality rates (AAMRs) were standardized according to the 2000 U.S. Census. Joinpoint regression was utilized to calculate annual percentage change (APC), and an ARIMA model with Python 3.10 was used for mortality predictions. Results: A total of 365,608 cardiac arrest-related deaths were recorded in the USA from 1999 to 2023. There was a sharp decline in mortality rate until 2001 (APC: −10.35, p < 0.05), followed by a slowed decline until 2013 (APC: −2.91, p < 0.05), and then a gradual uptrend. Males exhibited a higher AAMR (5.8, 95% CI: 5.8–5.9) compared to females (4.2, 95% CI: 4.1–4.2). African Americans had the highest AAMR (8.9, 95% CI: 8.9–9), followed by Caucasians (4.8, 95% CI: 4.8–4.9) and American Indians (3.5, 95% CI: 3.3–3.7). The South region of the US had the highest AAMR, followed by the Northeast, Midwest, and West. Alabama exhibited the highest AAMR, followed by Nevada and Hawaii. Predictive analysis suggests a potential stable slow downtrend in mortality rates by 2035 (AAMR: 4.28, 95% CI: −1.8–10.4). Conclusions: The observed trends and future predictions underscore the importance of targeted public health interventions and healthcare planning to address cardiac arrest mortality.

This study aimed to examine global hypertensive heart disease (HHD) trends (1990–2019). Methods: We extracted data from the Global Burden of Disease (GBD) 2019 Study, encompassing 204 countries and territories. We analyzed the age-adjusted mortality rates (AAMRs), crude mortality, prevalence, years lived with disability (YLD), years of life lost (YLL), and disability-adjusted life years (DALY). Joinpoint Regression Analysis was used to calculate the Annual Percentage Change (APC), with p < 0.05 indicating statistical significance. Results were stratified by region, Socio-Demographic Index (SDI), and gender. Results: Globally, the crude mortality rate for HHD rose from 12.2 (95% UI 9.9–13.6) to 14.9 (95% UI 16.5–11.1) deaths/100,000 population (1990–2019), whereas the AAMR declined from 19.3 (95% UI 5.8–21.6) to 15.1 (95% UI 11.1–16.7). A Joinpoint Analysis revealed significant APC shifts: a decrease of −1.53% (p < 0.05) from 1990 to 2006, an increase of +0.60% (p < 0.05) from 2006 to 2015, and a subsequent decrease of −1.28% (p < 0.05) from 2006 to 2019. Eastern Europe showed the highest annual rate of change in AAMR at 0.9 (95% UI: −0.1 to 1.2), whereas the high-income Asia Pacific region experienced the largest decline at −0.66 (95% UI −0.27–−0.72). Central Asian males had an AAMR of 31.1 (95% UI 35.3–22.9) in 2019, and Sub-Saharan African females reached 38.5 (95% UI 48.4–26.3). YLL trended downward in both sexes (APC: −1.94, p < 0.05 in males; −1.81, p < 0.05 in females), yet YLD rose steadily in recent years, underscoring a growing chronic burden. The AAMR was highest in 2019 among Sub-Saharan African females, which is a particularly important area. Conclusions: Targeted strategies are essential to mitigate the escalating HHD burden.

Non-obstructive hypertrophic cardiomyopathy (nHCM) remains a therapeutic challenge, with limited pharmacological options beyond symptomatic management. Mavacamten, a selective allosteric cardiac myosin inhibitor, has shown benefit in obstructive HCM, but its role in nHCM is uncertain. A systematic search of PubMed, Embase, CENTRAL, and ClinicalTrials.gov was conducted up to November 2025 for placebo-controlled randomized controlled trials (RCTs) enrolling patients with nHCM. Outcomes included Kansas City Cardiomyopathy Questionnaire (KCCQ) score, peak oxygen consumption (pVO₂), New York Heart Association (NYHA) functional class, and treatment-emergent adverse events (TEAEs). Pooled mean differences (MDs) and risk ratios (RRs) were estimated using random- or fixed-effects models based on heterogeneity. Two RCTs (n = 639) met inclusion criteria. Mavacamten showed a nonsignificant improvement in KCCQ (MD: 2.12; 95% CI: –0.98 to 5.22; I² = 0%) and peak oxygen consumption (MD: 0.36 mL/kg/min; 95% CI: –0.20 to 0.92; I² = 0%). No significant difference was observed in NYHA class improvement (RR: 1.15; 95% CI: 0.93 to 1.43; I² = 0%). TEAE incidence was similar between groups (RR: 1.11; 95% CI: 0.34 to 3.58; I² = 40.8%). Atrial fibrillation occurred more frequently with mavacamten (RR: 1.41; 95% CI: 1.28 to 1.56), whereas palpitations and dizziness did not differ significantly. Mavacamten does not significantly enhance symptoms, functional capacity, or health status in nHCM, though safety is comparable to placebo. Ongoing monitoring for arrhythmias and reduced ejection fraction is essential. Larger, longer-term studies are needed to clarify its role in this population.